Disrupting TSLP–TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases
Sign Up to like & getrecommendations! Published in 2024 at "EMBO Molecular Medicine"
DOI: 10.1038/s44321-024-00085-3
Abstract: Thymic stromal lymphopoietin (TSLP) is a key player in atopic diseases, which has sparked great interest in therapeutically targeting TSLP. Yet, no small-molecule TSLP inhibitors exist due to the challenges of disrupting the protein–protein interaction… read more here.
Keywords: tslp receptor; tslp; small molecule; atopic diseases ... See more keywords